Personalized Cancer Vaccine Cuts Melanoma Risk by 42%
New trial shows mRNA vaccine combined with Keytruda slashes melanoma recurrence and death risk by nearly half.
2 min read
Pharmaceutical giants Merck and Moderna have announced groundbreaking results from a Phase 3 trial, revealing that a personalized mRNA vaccine, when used in conjunction with the immunotherapy drug Keytruda, significantly reduces the risk of melanoma recurrence or death. The study, which involved 1,137 patients with Stage IIB-IV melanoma, found that the combination therapy reduced the risk of cancer recurrence or death by 42% compared to Keytruda alone.
Significant Survival Rates Observed
At two years, 82.2% of patients who received the personalized vaccine alongside Keytruda remained alive without melanoma recurrence, compared to 70% of those receiving Keytruda alone. The treatment also lowered the risk of cancer spreading to distant parts of the body or death by 38%. These results suggest a promising new approach in the fight against melanoma.
How the Vaccine Works
The vaccine is tailored to each patient’s unique tumor. Scientists use genetic sequencing to identify mutated proteins specific to cancer cells and then use mRNA technology to train the immune system to recognize and attack these proteins. This personalized approach aims to create a targeted immune response against the cancer.
Future Research and Challenges
Researchers are now exploring the potential of therapeutic vaccines for other cancers, including kidney, bladder, non-small-cell lung, and pancreatic cancer, as well as glioblastoma, a particularly aggressive brain tumor. While the findings are encouraging, experts emphasize the need for long-term follow-up to assess the vaccine’s continued effectiveness and its impact on overall survival.
Dr. Robert Vonderheide, director of the University of Pennsylvania’s Abramson Cancer Center, noted that while this is a significant step forward, much remains to be learned about its application across different types of cancer. Dr. Shirin Bajaj, incoming director of head and neck melanoma at Mount Sinai, highlighted the logistical challenges of scaling the treatment widely, acknowledging that while the logistics are not insurmountable, they will require careful planning and execution.
Source: Daily Wire
